Evidence
DNA Repair (Amst). 2024 Apr 11;139:103678. doi: 10.1016/j.dnarep.2024.103678. Online ahead of print.
ABSTRACT
Alzheimer disease (AD) is the most prominent form of dementia and has received considerable attention due to its growing burden on economic, healthcare and basic societal infrastructures. The two major neuropathological hallmarks of AD, i.e., extracellular amyloid beta (Aβ) peptide plaques and intracellular hyperphosphorylated Tau neurofibrillary tangles, have been the focus of much research, with an eye on understanding underlying disease mechanisms and identifying novel therapeutic avenues. One often overlooked aspect of AD is how Aβ and Tau may, through indirect and direct mechanisms, affect genome integrity. Herein, we review evidence that Aβ and Tau abnormalities induce excessive genomic stress and impair genome maintenance mechanisms, events that can promote DNA damage-induced neuronal cell loss and associated brain atrophy.
PMID:38669748 | DOI:10.1016/j.dnarep.2024.103678
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Genomic stress and impaired DNA repair in Alzheimer disease
🌐 90 Days
VR Related Evidence Matrix
- P2Y1 receptor in Alzheimer's disease
- Corrigendum to
- Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs
- G-protein coupled estrogen receptor 1, amyloid-β, and tau tangles in older adults
- The vascular contribution of apolipoprotein E to Alzheimer's disease
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
- Disease-Modifying Treatments and Their Future in Alzheimer's Disease Management
- Generating PET scan patterns in Alzheimer's by a mathematical model
- Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease
- Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology
- Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates
- In vivo PET classification of tau pathologies in patients with frontotemporal dementia
- How calcineurin inhibitors affect cognition
- Epigenetic modifications of DNA and RNA in Alzheimer's disease
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies
- The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome
- A multiscale closed-loop neurotoxicity model of Alzheimer's disease progression explains functional connectivity alterations
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Towards cascading genetic risk in Alzheimer's disease
- The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes
- Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid
- Brain-targeted Tet-1 peptide-PLGA nanoparticles for berberine delivery against STZ-induced Alzheimer's disease in a rat model: Alleviation of hippocampal synaptic dysfunction, Tau pathology and amyloidogenesis
- Using Drosophila amyloid toxicity models to study Alzheimer's disease
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- Influences of amyloid-beta and tau on white matter neurite alterations in dementia with Lewy bodies
- Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment
- Exploring the potential of quercetin in Alzheimer's Disease: Pharmacodynamics, Pharmacokinetics, and Nanodelivery systems
- Navigating the metabolic maze: anomalies in fatty acid and cholesterol processes in Alzheimer's astrocytes
- Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer's disease and related dementias
- Addressing the Discrepancies Between Animal Models and Human Alzheimer's Disease Pathology: Implications for Translational Research
- A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function
- D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease
- Parvalbumin interneuron cell-to-network plasticity: mechanisms and therapeutic avenues
- Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3
- Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
- The complexity of extracellular vesicles: Bridging the gap between cellular communication and neuropathology
- What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- Fixel-based analysis reveals tau-related white matter changes in early stages of Alzheimer's disease
- Innate immune activation in neurodegenerative diseases
- Memory Circuits in Dementia: The Engram, Hippocampal Neurogenesis and Alzheimer's disease
- Oxidatively-induced DNA base damage and base excision repair abnormalities in siblings of individuals with bipolar disorder DNA damage and repair in bipolar disorder
- Precision proteoform design for 4R tau isoform selective templated aggregation
- Mitochondrial DNA Disorders: the (long and winding) road to treatment
- Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
- Stem Cell Interventions in the Treatment of Alzheimer's Disease
- A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides
- Biomarkers of neurodegeneration in schizophrenia: systematic review and meta-analysis
- PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease
- β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer's disease
- mRNA-responsive two-in-one nanodrug for enhanced anti-tumor chemo-gene therapy
- Passive immunotherapy for Alzheimer's disease: challenges & future directions
- Do microbes play a role in Alzheimer's disease?
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- Data-driven decomposition and staging of flortaucipir uptake in Alzheimer's disease
- Genetic Determinants of Vascular Dementia
- Bacteroidota inhibit microglia clearance of amyloid-beta and promote plaque deposition in Alzheimer's disease mouse models
- A Comprehensive Review and Androgen Deprivation Therapy and Its Impact on Alzheimer's Disease Risk in Older Men with Prostate Cancer
- Ageing-Related Neurodegeneration and Cognitive Decline
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting
Evidence Blueprint
Genomic stress and impaired DNA repair in Alzheimer disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Genomic stress and impaired DNA repair in Alzheimer disease
🌐 365 Days
VR Related Evidence Matrix
- Microglial inflammation in genome instability: A neurodegenerative perspective
- P2Y1 receptor in Alzheimer's disease
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- Corrigendum to
- Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs
- G-protein coupled estrogen receptor 1, amyloid-β, and tau tangles in older adults
- The vascular contribution of apolipoprotein E to Alzheimer's disease
- Tau and Alzheimer's disease: Past, present and future
- Is Alzheimer disease a disease?
- Alzheimer's disease biomarker analysis using targeted mass spectrometry
- Understanding the mechanisms of disease modifying effects of aerobic exercise in people with Alzheimer's disease
- Deregulation of the Glymphatic System in Alzheimer's Disease: Genetic and Non-Genetic Factors
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- GLP-1/Sigma/RAGE Receptors: An evolving picture of Alzheimer's Disease pathology and treatment
- Neuropathology of Alzheimer's Disease
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Memantine versus Ginkgo biloba Extract: A Comparative Study on Cognitive Dysfunction Treatment in a Novel Rat Model
- Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
- Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability
- Alzheimer's Type Neuropathological Changes in a Patient with Depression and Anxiety: A Case Report and Literature Review of Neuropathological Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease
- Nonlinear changes in delayed functional network topology in Alzheimer's disease: relationship with amyloid and tau pathology
- The contribution of DNA methylation to the (dys)function of oligodendroglia in neurodegeneration
- Disease-Modifying Treatments and Their Future in Alzheimer's Disease Management
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- Discovery of Orally Available and Brain Penetrant AEP Inhibitors
- Nanopore-based DNA long-read sequencing analysis of the aged human brain
- Generating PET scan patterns in Alzheimer's by a mathematical model
- Navigating the Dementia Landscape: Biomarkers and Emerging Therapies
- Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease
- A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
- Microglial TLR4/NLRP3 Inflammasome Signaling in Alzheimer's Disease
- Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology
- Ketone bodies mediate alterations in brain energy metabolism and biomarkers of Alzheimer's disease
- COVID-19 and Alzheimer's Disease Share Common Neurological and Ophthalmological Manifestations: A Bidirectional Risk in the Post-Pandemic Future
- The Role of RIN3 Gene in Alzheimer's Disease Pathogenesis: a Comprehensive Review
- Effects of heterologous human tau protein expression in yeast models of proteotoxic stress response
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Treatment of the CRND8 mouse model for cerebral amyloid angiopathy, exhibited increased levels of neuron specific enolase in brain tissue following long-term treatment with a modified C5a receptor agonist, accompanied by improved cognitive function
- Decoding metabolic signatures in Alzheimer's disease: a mitochondrial perspective
- Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates
- Alzheimer's Disease: The Past, Present, and Future of a Globally Progressive Disease
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease
- Low-dose brain radiation: lowering hyperphosphorylated-tau without increasing DNA damage or oncogenic activation
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer's disease
- Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)
- Self-Aggregating Tau Fragments Recapitulate Pathologic Phenotypes and Neurotoxicity of Alzheimer's Disease in Mice
- In vivo PET classification of tau pathologies in patients with frontotemporal dementia
- Radiotherapy in Alzheimer's Disease: A Systematic Review
- CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease
- How calcineurin inhibitors affect cognition
- Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone
- Alpha-, Beta-, and Gamma-Secretase, Amyloid Precursor Protein, and Tau Protein Genes in the Hippocampal CA3 Subfield in an Ischemic Model of Alzheimer's Disease with Survival up to 2 Years
- Evaluation of possible neuroprotective effects of virgin coconut oil on aluminum-induced neurotoxicity in an in vitro Alzheimer's disease model
- Epigenetic modifications of DNA and RNA in Alzheimer's disease
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Senile plaque-associated transactive response DNA-binding protein 43 in Alzheimer's disease: A case report spanning 16 years of memory loss
- The elusive role of herpesviruses in Alzheimer's disease: current evidence and future directions
- Local structural preferences in shaping tau amyloid polymorphism
- Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies
- Emerging evidence for dysregulated proteome cargoes of tau-propagating extracellular vesicles driven by familial mutations of tau and presenilin
- A new metal ion chelator attenuates human tau accumulation-induced neurodegeneration and memory deficits in mice
- The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome